Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

BioArctic, Audiocast with teleconference, Q1'24

By Inderes5/17/2024, 7:30 AM
BioArctic

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Gunilla Osswald
00:01 - 17:43

Good morning and welcome to BioArctic AB's presentation for the first quarter of 2024. It's very exciting times for BioArctic AB with Leqembi, which is originating from BioArctic AB. Leqembi can be the first and only disease-modifying treatment for Alzheimer's disease with full approval so far in the US, Japan, and China. There will be three key messages today. I'll talk about Leqembi sales, which we see is increasing. The infrastructure has been established to a large extent in the US, and the launch now goes into the next expansion phase. The second part is that the lecanemab regulatory process continues with more approvals, and China was approved earlier this year. And more submissions are also being filed by Eisai, including a subcutaneous auto-injector file. The third aspect and key message is also around the rest of our portfolio, which is progressing really well. And we have made our first agreement on the project, which is utilizing our BrainTransporter technology. And I'll talk more about all this here today. Next slide please. I'm Gunilla Osswald, the CEO of BioArctic AB, and I will share today's presentation with our CFO, Anders Martin-Löf, and Anna-Kaija Grönblad. Our Chief Commercial Officer is also here for the Q&A after the presentation. Next slide please. BioArctic AB is listed at Nasdaq Stockholm large cap. And this is our disclaimer. Next slide please. BioArctic AB focuses on disease modifying treatments for neurodegenerative diseases. And we are now on the market with Leqembi for Alzheimer's disease, and we are preparing for phase two in Parkinson's disease. These are areas where there is a huge unmet medical need and very large patient populations that we aim to help. We have a great organization with highly skilled scientists and drug developers with vast experience, and we are now building a commercial organization to prepare, and we are preparing for commercialization together with our partners ACI and Eisai in the Nordic region. We have a broad portfolio building on the success of the campaign with very selective antibodies for Alzheimer's disease, Parkinson's disease, and ALS. And we also have our very encouraging BrainTransporter technology, which helps us to get the antibodies better into the brain. I'm very encouraged by that. Our portfolio is exactly where the science is now evolving quickly. We are also well financed,as we have approximately 1 billion Swedish crowns in the bank. And finally, the fact that our science and company leadership throughout the years have been given numerous awards validates our innovation and global leadership position within neurodegenerative diseases. And we also got some new awards during this quarter. Next slide please. So a lot of things have already happened this year. The year started with the approval of Leqembi in China, while Eisai is planning for a launch in July in Europe. It was disappointing that the Scientific Advisory Group meeting was annulled due to process issues that were not dependent on lecanemab. So the Scientific Advisory Group meeting has to be rescheduled. As the Alzheimer's and Parkinson's Congress was held earlier this year. There was a very positive atmosphere with a lot of excitement in the fields of Alzheimer's disease and Parkinson's disease. And with regard to the blood-brain barrier technologies, BioArctic and Professor Lars Landfall presented new data on Lecanemab, further supporting the unique binding profile with lower kappa binding, which is linked to a lower incidence of the side effect. If you compare this with competitors, As I mentioned, more data supporting the disease-modifying properties and more data suggesting even better effects if you start early with the treatment in early Alzheimer's disease were presented, as well as data supporting subcutaneous as a more convenient administration alternative for Lecanemab. Eisai has submitted a supplementary application to the FDA for less frequent dosing interventions with Lecanemab. And earlier this week, Eisai also initiated a rolling application to the FDA for Lecanemab with regard to the subcutaneous auto-injector for maintenance dosing. BioArctic and Eisai have entered into a research evaluation agreement regarding BAN2802, which is an Alzheimer's project utilizing our BrainTransporter technology. And this is then the first agreement utilizing our technology. And I expect more to come. BioArctic was included in Nasdaq's new ESG Responsibility Index, which we are also happy about. Next slide, please. Lecanemab is the first disease-modifying treatment for Alzheimer's disease with full approval in the US, Japan, and China, and it is on its way to being established as a new standard of care for Alzheimer's patients. A lot of things are happening around the world, and if we start with the US, where it is approved and broadly reimbursed since July last year, Eisai has also submitted two files for more convenient maintenance dosing, a supplementary application for less frequent IV dosing, and a new sBLA for a subcutaneous auto-injector administration for maintenance treatment. The launch is ongoing and now progressing into the next expansion phase. In Japan, Lecanemab was approved in September and the launch started in late December and it is progressing really well. In Europe, as I said, we are waiting for the new Scientific Advisory Group meeting and that will be followed by a CHMP opinion meeting. And we are hoping, of course, for a positive opinion and a European Commission approval in late Q3. In China, approval was granted in January and Eisai is preparing for a launch in July. Lecanemab regulatory files are being reviewed in many parts of the world right now, and we are hoping for several positive responses during the coming months. So I think it's a very exciting time. Next slide, please. The launches are also progressing now at a very good pace. So if we start with the US, where a lot of work has been done by Eisai to prepare the market and establish the pathway together with hospitals and infusion centers, etc., there's a strong momentum with 97% of the 100 integrated delivery networks, which are groups of hospitals and so forth. And Eisai is now expanding their focus to the top 150 integrated delivery networks. I think it's great that the prescribing facilities have been established in a broad way and can be found across the US. Many prescribing physicians have gone through a trial period, and they are now in the expansion phase. We have heard that some facilities are confirming more than 200 cases of Lecanemab treatment. It's also reassuring to see that the real world evidence of Lecanemab being used in clinical practice shows that the side effects are in line with the results of clinical trials as described in the US package insert. I think that shows that Lecanemab appears to be used safely and in the right way in clinical practice. So in summary, now that the pathway has been established, to a large extent, a site takes the launch to the next stage and that is the prescription expansion phase. Eisai and their partner Biogen are strengthening the go-to-market structure with the aim of providing tailored information regarding three things. The first is, of course, regarding Leqembi. The second is regarding reimbursement and support for patients. And the third is around system efficiency in order to shorten the time for treatment. More and more patients can now benefit from the treatment of Leqembi in the US. Next slide, please. If we then look at Japan, the launch is progressing even faster than expected here with fast establishment of the diagnosis and treatment pathway at 600 facilities within four months of launch. I think that's very impressive. I think it's further impressive that the Japanese launch is even exceeding Eisai's initial targets. And it's clear that the broad spectrum of promotional activities towards healthcare professionals are efficient. Would I look at China? The launch is planned for July, and here China is a bit different. Um, and that is, for example, that there will initially be a focus on the private market. Furthermore, Eisai will be leveraging already established online health platforms. And the diagnosis. The streamlined diagnosis will mainly be utilizing blood-based biomarkers. And that I think, will be very important and key drivers for diagnosis and growth. Next slide, please. Eisai also continues to develop Lecanemab, and the first approval in the US, Japan, and China is for intravenous administration ten milligrams per kg bi-weekly, and that is both for initiation and maintenance treatment. The file is also under regulatory review in many other regions. As I said, in order to increase the convenience for the patient. Eisai has now also made two applications to the FDA for more convenient maintenance. Dosing. After the initiation phase, then the maintenance phase could continue with either monthly ten milligrams per kg as described in the supplementary application. The other application was a rolling submission under Fast Track designation, and that was initiated by Eisai this week. And that is regarding a subcutaneous injection with an auto-injector with a fixed dose of 360mg for maintenance dosing. The next step, which will be very important, is when the subcutaneous auto-injector can be used both for initial and maintenance treatment. And here, Eisai has initiated discussions with the regulatory authorities. I think that their long-term penetration will also be supported by simplified diagnosis with blood-based biomarkers. And I think it's reassuring to see how well the blood-based biomarkers are evolving over the world. Next slide, please. I think it's great to see how Leqembi brings value to patients, caregivers, and society. Leqembi has been studied in a broad patient population with early Alzheimer's disease and has shown a consistent and distinct efficacy and safety profile. I think it's very encouraging to note that data from the lower dose group, which is then at a very early stage of early Alzheimer's disease, suggest a potential even greater treatment benefit. And that is when you start the treatment at an early stage of mild cognitive impairment. An early start and long-term treatment bring greater benefits for patients. Reports on the side effects. ARIA from real-world clinical practice are consistent with what was observed in the clinical trial, as described in the US prescribing information. Most reports are non-serious, asymptomatic, and occur early in the treatment. I think this indicates that safety can be appropriately monitored. The low levels of antidrug antibodies further enable maintenance treatment effectiveness for Leqembi. The improvement in dosage and administration is important for continued treatment. And as I just described, Eisai has filed for both IV and subcutaneous maintenance treatment in a more, um, in a better way for the patients. The subcutaneous auto-injector will be a great improvement for patients to enable easier administration at home, and this will also be less burdensome on healthcare, of course. The ongoing phase three study. Ahead, three, four, five is for pre-clinical aid, and I will talk about very early stages of Alzheimer's disease. This is before the subjects have symptoms. And this, uh, study could potentially lead to a further expansion of indications into the even earlier stages of Alzheimer's disease. And this could also potentially further expand the clinical benefit for the subjects. So I think that Leqembi brings a lot of value for many. Next slide, please. But I want to emphasize that even though Leqembi, of course, is of main interest, BioArctic is more than Leqembi. And I want to mention two other pipeline highlights. The first one is regarding the BrainTransporter technology at the Alzheimer and Parkinson Congress. It was highlighted that active transport of antibodies into the brain is seen as the next big step for neuroscience. Our proprietary BrainTransporter technology continues to progress very well. And by utilizing our BrainTransporter technology, we get a rapid, broad, and deep distribution of the antibodies into the brain, and this could potentially lead to even better efficacy and tolerability and with lower doses, of course. I want to emphasize three of our projects utilizing this technology. First, the two Alzheimer programs, BAN2802, where we now have signed a research evaluation agreement with Eisai as the first agreement utilizing our BrainTransporter technology and expect more agreements to come here. The second project is BAN2803, which is the primary gluAB antibody utilizing the BrainTransporter technology. This looks very promising, and we have increased our investments here and we are actively progressing this project towards the clinical stage. In Parkinson's disease. The project, called PDB2238, is an alpha-synuclein antibody with BrainTransporter technology. It's developing really well and we are actively progressing towards a candidate drug nomination. Next slide please. The other highlight of our pipeline that I want to mention here today is regarding our alpha-synuclein program. And at the Alzheimer and Parkinson Congress, again, encouraging data on alpha-synuclein treatments were presented, as well as great progress on diagnosis and biology linking into alpha-synuclein. This further supports our alpha-synuclein programs, both Exidavnemab as well as 2238. X, which is our selective alpha-synuclein antibody, where we are preparing for phase two. And the phase two study is called EXIT. And that is for Parkinson's patients. And we plan to start dosing late this year. The aim of this study will be safety and tolerability and pharmacokinetics with exploratory biomarkers including seeding, amplification, assay and digital biomarkers. The study protocol is currently being finalized through interactions with regulatory authorities. The drug product is now available and the study is planned to be performed in Europe, with the first patient planned to be dosed, as I said, late this year. Next slide please. So just to summarize, BioArctic's portfolio in Alzheimer's, Parkinson's, ALS and the BrainTransporter technology are most advanced. The program is of course Lecanemab. But I want to emphasize again that BioArctic is even more than Lecanemab. And after the Alzheimer's and Parkinson's Congress, we can again conclude that our portfolio includes exactly the targets and trends where science is breaking now. And I'm pleased to see the continued progression of our project here and how well it's being developed. Next slide please. And then I will hand over to Anders Martin-Löf for the financial summary.

Anders Martin-Löf
17:43 - 24:56

Thank you, Gunilla. If we turn to slide 15, as Gunilla has already mentioned, the launch is progressing really well and now we're starting to see that in our financials. The global lecanemab sales were ¥2.82 billion in the quarter. That's roughly 220 million Swedish or $80 million. And that represented a 170% increase over Q4 2023. On that, we get the royalty rate of 9% on global net sales. In addition, we get 1% more on US sales and 1.5% on sales that we then pass through to our partner, LifeArc. So the 21.3 million in revenues that we recorded during the first quarter, that includes the pass-through royalties we pass on. But you see a very, very steep increase quarter over quarter. And this growth is likely to continue during the year. The US launch is now in the expansion phase. As I mentioned, Eisai and Biogen are increasing their sales force to drive sales not only in the larger hospitals, but now in their satellite clinics. We have seen a strong start in Japan. The pathway has been established at 600 sites, but more and more sites are coming online. So we'll see very steep growth there as well. And the launch is planned for China in July, and that will further support the growth during the year. If you turn to the next slide, you can see that Eisai has, for the very first time, issued the forecast for near-term sales. And they are predicting more than a tenfold increase in sales of Leqembi from 2023 to 2024, going from ¥4.3 billion, roughly 300 million Swedish in 2023 to ¥56.5 billion, i.e. 3.9 billion Swedish in 2024. Um. The lion's share of the market will come from the US. So 77% is expected to come from the US, but already 18% is expected to come from Japan. Um, for us, this would then correspond to a royalty of roughly 400 million in recorded revenue, or roughly 360 million net after the royalties paid out to LifeArc. And in the coming year, this is likely to continue. We have briefly mentioned that the subcutaneous maintenance formulation is likely to be approved in 2025. We will also see a subcutaneous, uh, formulation for initial treatment. And as I indicated, that could be, uh, approved in 2026. We're also seeing the implementation of blood-based biomarkers starting already this year in China. It's happening in Sweden. And we expect that to continue all over the globe. And all of this lowers the barriers to treatment. So when Eisai has predicted what's going to happen mid-term, they are expecting roughly a fivefold increase in sales from 2024 to 2026. And in their revenue simulation that they presented in March, they said that they would have revenues of ¥290 billion. So roughly 20 billion Swedish, or $1.9 billion in 2026. So we are really just at the beginning of the growth phase for the company. If we then turn to the next slide, uh, I'll go through our numbers for the quarter. Uh, on the left-hand side, you see that our first quarter net revenues were 30 million. That's quite a big drop from a year ago when we had 393 million in revenues. But that's explained by the fact that we had three milestones totaling €35 million in the first quarter of 2023, and there were no milestones paid during this quarter. We are still entitled to more milestones. We are expecting a milestone when we get approved in the EU this year and in the following years. We are entitled to sales milestones in '25, '26, and '27. So that will continue. But over time the two new revenue streams will take over more and more. Right now, the revenue was 21 million promotional or 3 million. But over time, those two revenue streams will, of course, make up the lion's share of our revenues. And that will increase the lumpiness of our revenues. And they're obviously very lumpy right now, but over time it will be much, much smoother. If we return to the middle graph, you see our operating expenses. And first, this is the first time you see them by function. So the total operating expenses increased to 101 million from 79 million in the first quarter. 75% of that increase comes from R&D. Uh, and you mentioned that 63% of our operating expenses come from R&D, and that's an increase from last year, when 59% of our operating expenses came from R&D. On top of that, we have 12% of our expenses coming from sales and marketing. These two ratios will continue to increase. Our costs will increase during 2024 due to the fact that we are investing heavily in the programs, especially the ones for which we are starting our phase two trial production later this year. We're also investing in our Alzheimer's programs, where we selected our candidate drugs last year and are now performing IND-enabling studies. We're also building up our commercial organization, which will accelerate towards the latter part of the year. So we are expecting a continued increase. But more and more, a larger and larger share of course will be from R&D and sales and marketing rather than G&A. On the left-hand side, you see our operating profit, which was negative. So it was an operating loss of 73 million for the first quarter, which is roughly in line with what we saw in the fourth quarter last year. If we look at our financial position on the next slide, starting from the right-hand side, you see that our net loss was 58 million, which is roughly 50 million better than the operating loss. And that is explained by a fairly strong financial net loss of 15.7 million during the quarter. On the middle graph, you see, on the other hand, that our operating cash flow was weaker than our operating result, and that is due to the fact that the royalty payments are lagging the royalty revenues by roughly two quarters. So in this quarter, we saw a 45 million increase in working capital. And this will continue to increase as our royalties increase. So this lag will continue. But it has a very limited impact on our financial position. You see on the right-hand side that we have a cash position, including short-term investments, of 991 million. So we can continue to work long term to focus on advancing our portfolio in the fastest possible way without thinking too much about financials. Looking ahead for the remainder of the year. I think it's unlikely that we will be profitable in 2024, but as royalties grow, I think there's a very high likelihood that we will be profitable again in 2025 and onwards. That was all from my end, and I had to walk back to Geneva for some closing remarks.

Gunilla Osswald
24:57 - 27:44

Thank you so much. And now we are coming to the final part of the presentation with some closing remarks and upcoming news flow. Next slide please. So, the upcoming news flow this quarter includes the initiation of the US submission of Lecanemab for the subcutaneous auto-injector maintenance dosing under the fast track designation, which was just achieved this week, and we are hoping for an approval of Lecanemab in Great Britain. If we look at the next quarter, we are looking forward to the next big Congress for Alzheimer's, called the AIC, which is in Philadelphia during the summer. And there we will see more presentations on Lecanemab and more interesting data. In July, Assi plans to launch Leqembi in China. And in Europe. We of course hope for a positive opinion after a new scientific advisory group meeting. And if so, then we could expect an EU approval during late Q3 and then during the fourth quarter of this year, we plan to start the phase two study in Parkinson's disease with Exidavnemab, and we're looking forward to being able to present some more data on our BrainTransporter technology programs. Other potential approvals of Leqembi could also come during the rest of the year. So I think it's a lot of exciting times ahead for biotech. Next slide please. So to summarize, today's presentation covers Leqembi being approved in the US, Japan, and China for huge patient populations with early Alzheimer's disease. And even if a small part of the population will have treatment with Leqembi, that will be huge. And I think it's gratifying that we can help many patients. The launch is showing strong momentum now, and it will be exciting to see more and more patients being able to get access to Leqembi treatment. We are hoping for more approvals and Eisai continues with more regulatory applications and further development of the camera. Our pipeline is progressing very well and the first BrainTransporter agreement has been signed. Our finances remain solid. We have almost 1 billion Swedish crowns in cash, which I think is great, so we can focus on driving the project forward towards the patient. Next slide please. So BioArctic's aim is to improve the lives of patients with neurodegenerative disorders. And I think we are very well on our way. And I think it's extremely gratifying that we now can help more and more patients and their families. And by that, I say, thank you so much for your attention and we're happy to take questions.

Operator
27:47 - 28:11

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Alastair Campbell from Royal Bank of Canada. Please go ahead.

Unknown 1
28:13 - 28:58

Hi there. Thanks very much for taking my questions and it's great to see Leqembi gaining momentum in the US. Um, two questions please. First of all, on AHEAD 345. Just looking at the status on clinicaltrials.gov, it looks like that's now primary completion around 2029. So I guess if you give me an update on how recruitment is going and sort of what the time frame looks like for that, and frankly, you know, if it reads out in 2029, gets on the label 2030, um, what sort of time frame do you have left to sort of get a commercial benefit from that, given the contract in place? And then the second question is just simply on cash position, given potential milestones later this year. Um, what do you feel about, uh, whether cash may end at the end of the year? Thank you.

Gunilla Osswald
29:00 - 30:24

Thank you so much for your questions. So, um, if we look at the AHEAD 345 study in the very early, um, Alzheimer's disease, even before the subjects had any treatment. And the aim of this study is to have 1400 subjects. I think that the study is ongoing around the world, the majority in the US, but also in other parts of the world. I think the inclusion is going really well, and Eisai is hoping to conclude the enrollment into this trial during this year. And then it's a four-year treatment in this trial. Um, and then we will wait and see the results. But I'm really encouraged by the data that we have seen with very early patients of mild cognitive impairment that they seem to maybe have even more benefit. Um, and then thinking about when this can be ready, it's, um, I will not speculate exactly on when that can be. Um, but our patent expiry, including extension, is around 2032. So I think that there is still time for that. And then, you also asked about more milestones, and I have that question to answer.

Oskar Bosson
30:24 - 30:25

Yeah.

Anders Martin-Löf
30:25 - 30:41

You asked about the cash position towards the end of the year and assuming that we get approval in Europe, which we believe will happen during the second half, we're assuming that we will have a cash position between 800 and 900 million towards the end of the year in Swedish. Thank you.

Unknown 1
30:41 - 30:42

Thanks much. Thank you.

Operator
30:50 - 30:56

The next question comes from Joseph Hedden from Arc Securities. Please go ahead.

Joseph Hedden
30:59 - 32:01

Good morning, and thanks for taking my questions. Um, just referring to your news flow slide and in particular the potential EU approval. Um, I know some of the language you use in terms of the scientific advisory group. Could you just fill us in? Has this happened to your knowledge yet? And if it hasn't. Do you have any idea when this could happen? Just trying to get a sense of what the risk to that timeline still is. Um, and then secondly, it's clear that blood-based biomarkers are quite important to Eisai, uh, for projections. Um, and it's something that you and I talk about a lot. Um, I just wanted to get an idea. Does Eisai have any deals with providers of these tests in the space currently, or has it got any proprietary technology? Um, and also, are there any data on the real-world use of any of the available tests so far in the launch? Thank you.

Gunilla Osswald
32:03 - 34:15

Thank you so much, Joseph. Great questions. So first of all, with regard to Europe and the Scientific Advisory Group, it has not happened yet. We are looking forward to seeing how it evolves. And I think that the timelines that we have laid out are realistic. We don't know exactly when the different events will happen. But I really hope for a positive opinion here. And approval. So European patients can also get access to Leqembi. Your second question regarding the blood-based biomarkers, I think it's evolving really well. Our partner Eisai has said that they have different collaborations, for example, with C2N and with Zeiss Max and so forth. And I think you should ask them more about this, but this is what we know so far. And I think that at the Alzheimer's Congresses, there are presentations every time about more and more solid data coming from the blood-based biomarkers. And it's about a better beta-42 over beta-40 ratio, but especially about the phospho-tau biomarkers, which are evolving really well. So this is being utilized already, here in Sweden, in clinical practice, and it's being tested in China. It's also being used for triaging in other parts of the world, including in the US, starting there. I think it will be used more broadly in a clinical setting in a couple of years. So, it looks really good. It's already used also, for example, in the screening phase of the head study, where the first part is linked to a blood test, and in that screening phase, it helps to see. And then it's followed up by other biomarkers. So I really strongly believe in the blood-based biomarkers that will significantly help to find the right patients who can benefit.

Joseph Hedden
34:19 - 34:21

Okay. Thanks. That's great. Thank you.

Gunilla Osswald
34:22 - 34:22

Thank you.

Operator
34:30 - 34:36

The next question comes from Patrick Lin from DNB Markets. Please go ahead.

Gunilla Osswald
34:39 - 34:40

Yes.

Unknown 1
34:40 - 34:41

Good morning, everyone.

Unknown 2
34:41 - 34:55

Maybe just to start with a follow-up question to Joseph’s question about the SAG meeting. You said that it hasn't happened yet, but has it been scheduled? So we know when it's going to be.

Gunilla Osswald
34:57 - 35:14

So, it has not happened yet. And, uh, we don't have all the details about how and when it will happen. So we need to come back to that when we know more. But I think that the timeline I laid out, um, I believe in those. Okay. We have to wait. Nothing more.

Unknown 2
35:15 - 35:42

Okay, great. Right then, I actually had a follow-up on this research evaluation collaboration that you have with Eisai on BAN2802. Maybe if you could give us a little bit more color on what that actually includes, what will happen, what are the timelines, what type of evaluations are you doing together and so on.

Gunilla Osswald
35:43 - 37:02

Yeah. So I think this is regarding the project called BAN2802, and that's one of the two Alzheimer's projects that we are investing heavily in now. Um, and driving forward strongly, which is based on really selective antibodies combined with the BrainTransporter technology. And here we have laid out for BAN2802 a very clear development program that we will share the costs with Eisai. And that's a program which is about two years that we will be doing and then preparing this project for the clinical stage. So I'm really enthusiastic about this project, and I'm also really enthusiastic. I've got the question, so what about BAN2803? Does that mean you're not driving that forward? And I just must say that BAN2803 also looks really encouraging. So I think it's a very strong position for BioArctic to have two very good programs as it looks like, utilizing the BrainTransporter technology for Alzheimer's patients, as well as for Parkinson's disease, and also in the future for ALS and other diseases.

Unknown 2
37:03 - 37:10

Great. So first up now, it's a two year evaluation where you split the cost 50 over 50 I suppose.

Gunilla Osswald
37:11 - 37:36

So I'll not comment exactly on how. How the split is. But we will share the costs with Eisai, and then after that about two year period, then there would be an option for Eisai to go into a license deal. And that's of course, what the aim is for both companies to start this project and do the collaboration together.

Unknown 2
37:37 - 37:50

Great, great, great. Then. Then I also had a question about the assist trial. Uh, maybe I missed that. Or maybe you can just remind me. Uh, have you said anything about the potential size of that trial? How many patients you're going to include?

Gunilla Osswald
37:52 - 38:32

No, we have not. And I think that, uh, in the next, uh, Q1 report, we will reveal more information. It is; I should just be managing expectations. This is a small study, and it's really about safety and tolerability, where we will be looking at two different doses and comparing with placebo, but it's mainly about safety, tolerability, and pharmacokinetics, with some exploratory biomarkers. So it's really a study which is preparing us for the next important step. And that is to select the indication or indications for phase 2B, which will be the most important parts where we will be exploring full efficacy.

Unknown 2
38:33 - 39:07

Mhm. No. Because the reason I ask is, I mean, um. I mean, if you plan to include, you know, patients with basically five different, uh, indications, my impression before has been that, uh, you will have, uh, you will base on the results here, decide on where to continue with phase two. And my thinking was that maybe you needed, you know, a reasonably large amount of patients in these different indications to be able to, to, to actually decide where to go next.

Gunilla Osswald
39:08 - 40:57

Thank you for your question. Then I will help to clarify. The next study that we are now preparing will be done in Parkinson's patients. And that is, as I said, safety, tolerability, and that is not the study of such will not include different kinds of patient populations, different indications that will be decided based on several other, um, things and not based on, on, uh, the data as such in this study. I mean, it's for example, we'll be looking at competitors, which are also progressing in some of those indications. Uh, we will also look at where we think we have the largest possibility to be successful with regard to biomarkers and clinical efficacy endpoints and so forth. So I think it should be, um, clearly expected that, uh, this, this phase one package that has been done was a large phase one package with single doses, um, with, um, both, um, different doses and also IV and subcutaneous and also different ethnicities including Japanese patients and so forth. So but there has not been a multiple ascending dose studies done yet. So that's part of the phase two A study. So it's really about safety and tolerability. And a small study should be expected. And meanwhile that is ongoing. We will do a lot of strategic work looking at the different indications that potentially could come after and select the best indication for phase two B. So it will only be Parkinson's disease patients in the phase two A study, the safety and tolerability study. But that doesn't mean that it has to be Parkinson's disease patients only in the next step; it could be different indications. Did that help?

Unknown 2
40:58 - 41:03

Great. Uh, definitely. Definitely. I got it now. Great. Thank you very much, guys.

Gunilla Osswald
41:04 - 41:04

Thank you so much.

Operator
41:10 - 41:16

The next question comes from Frederick Thoré from RedEye. Please go ahead.

Unknown 1
41:17 - 41:18

Uh, hello.

Anders Martin-Löf
41:18 - 41:19

And thank you.

Unknown 1
41:19 - 41:20

Uh, my question.

Unknown 3
41:20 - 41:32

You maybe touched upon this a bit, but about cost development for '24. Uh, could you elaborate on this? And is it the same as before? Roughly a 30 to 50% increase from the previous year?

Oskar Bosson
41:34 - 41:34

Yes.

Anders Martin-Löf
41:34 - 41:41

We don't have an update yet. Uh, so we stand by our previous guidance.

Unknown 3
41:42 - 42:07

Okay. And my second question was about the subcutaneous maintenance dose, and also the potential for the initial dose to also be subcutaneous. Could you explain the difference between these two? How much of an increase, would you say, if the initial dose could also be subcutaneous compared to only for the maintenance?

Gunilla Osswald
42:10 - 43:50

But I think, of course, it's a very good first step, with the subcutaneous administration using an auto-injector, like a pen. Uh, so I think that will be a really good step for the longer-term maintenance phase. And that is what the submission that was just initiated was about. But of course, it's good to have the alternative to also start with a subcutaneous auto-injector. And as you may recall, I mentioned in a previous call that when I presented the data from the ongoing study with a subcutaneous auto-injector, it showed even better exposure and an even better reduction of plaques with the subcutaneous formulation. So that's why there is, of course, a discussion ongoing about which dose we should use for the initiation phase, and potentially also adjust the dose for the maintenance phase. Those are the discussions which are ongoing. And in order to sort that out, that will then help to determine when the initiation dose can be administered. But of course, that will really help the patients and be a very attractive alternative. And so, but I can't say exactly how much of the future sales are expected to be dependent on one or the other. I think it's really good to have different options and alternatives for the patients.

Unknown 4
43:51 - 43:52

Perfect.

Unknown 3
43:52 - 43:54

Yeah, that's all for me. Thank you.

Gunilla Osswald
43:54 - 43:55

Thank you so much.

Operator
44:00 - 44:07

As a reminder, if you wish to ask a question, please dial the pound key followed by five on your telephone keypad.

Unknown 2
44:10 - 44:12

So it doesn't seem

Anders Martin-Löf
44:12 - 44:13

Like there are any

Unknown 2
44:13 - 44:15

Telephone questions, but we have some

Unknown 1
44:15 - 44:16

Written questions.

Anders Martin-Löf
44:16 - 44:17

Coming in.

Unknown 2
44:17 - 44:19

So the first one was.

Unknown 1
44:19 - 44:20

About approval in.

Anders Martin-Löf
44:20 - 44:25

The EU, but I think you've already answered that, Gunilla, with the expected timeline of late Q3.

Unknown 1
44:25 - 44:29

This could be the timeline we are seeing right now. Um, but maybe.

Unknown 2
44:29 - 44:29

For you.

Unknown 1
44:29 - 44:30

Anders, too.

Anders Martin-Löf
44:30 - 44:32

Clarify a bit about the milestones.

Unknown 1
44:32 - 44:33

You mentioned.

Anders Martin-Löf
44:33 - 44:36

Something about that, but maybe we can clarify how much is still available.

Unknown 1
44:36 - 44:38

And expected milestones and when.

Anders Martin-Löf
44:38 - 44:39

That could happen.

Oskar Bosson
44:39 - 44:41

Yes. Thank you Oskar. Yes.

Anders Martin-Löf
44:41 - 45:13

So, in total, we have €84 million of outstanding milestones. As I said, we are expecting a milestone. When we receive approval in the EU, we cannot specify the exact magnitude of that. But when we received approval in the US, we received €25 million, and Europe's allocation was slightly smaller. So that would be slightly smaller than 25. The rest of the milestones are mainly sales-related. So you can basically assume that they will happen during 2025, 2026, and 10% of those spread out.

Oskar Bosson
45:13 - 45:14

Over those years.

Anders Martin-Löf
45:15 - 45:17

That's the milestone development.

Oskar Bosson
45:17 - 45:19

That's what we expected. Thank you.

Unknown 2
45:19 - 45:21

Anders.

Unknown 1
45:21 - 45:21

That we have written.

Oskar Bosson
45:21 - 45:53

Question also on the face-to-face study, but I think you clarified that at length in your response to Patrick. So, perhaps a question, or two, from the committee. The first one is if we could say anything about the number of patients currently on Lecanemab. And secondly, perhaps a bit more explanation on the BrainTransporter technology. And if that uses the transfer and receptor, such as similar to what Roche's Brain Shuttle or Denali's program does.

Gunilla Osswald
45:54 - 47:05

Yes, I think the BrainTransporter technology is definitely utilizing the transfer and receptor. Um, in the approaches that we're utilizing right now. And they have a lot of similarities with both Roche and Eisai, but they also have some important differences that we will be able to communicate more about later on. We are really encouraged by the Roche data that was presented at the previous Alzheimer Congresses, where they showed really impressive data. It's still early days, but this is the first clinical data that has been shown. And I think that really has made us focus and invest even more strongly in our BrainTransporter technology, because it really looks like the next generation of approach to get antibodies better into the brain. So I strongly, as you have heard before, believe in this. And there is a possibility for better effects, better side effect profiles, and lower doses. So, it has some clear similarities, but also some important differences.

Oskar Bosson
47:07 - 47:09

And do you want to say anything about the patient numbers?

Gunilla Osswald
47:10 - 47:10

No.

Unknown 1
47:11 - 47:12

Sir.

Oskar Bosson
47:12 - 47:15

And we don't know. I think that is the correct answer. We don't know.

Gunilla Osswald
47:15 - 47:29

Exactly. I think you have to rely on what we said concerning the number of files on the slides and also more about what we understand about the sales. So I think we have to stay there for now.

Oskar Bosson
47:29 - 47:30

Right.

Anders Martin-Löf
47:30 - 47:37

And as I commented on this and said that they will not communicate patient numbers going forward because it's really hard to estimate actual patient numbers.

Oskar Bosson
47:38 - 47:38

It's much.

Anders Martin-Löf
47:38 - 47:42

Better information to look at vials and numbers and actual.

Oskar Bosson
47:42 - 47:44

Sales. So there will be.

Anders Martin-Löf
47:44 - 47:46

No communication regarding that going.

Oskar Bosson
47:46 - 48:14

Forward. Thank you. Maybe just a follow-on from Goldman Sachs and Ryan about the BrainTransporter technology. He's wondering if we can say anything about when this might enter the clinic. And also if the collaboration with ACI regarding the Leqembi and BAN2802 program changes anything in the development plans that we have for that program or the other programs?

Gunilla Osswald
48:14 - 49:20

And so, I think it's, you know, that we see those two projects at the end of last year. And normally when we do a CD nomination, that means about two years to coming into the clinical space. So roughly, that's the timeline and does the collaboration change any of the development plans? What it does is that it makes us want to invest even more in all our BrainTransporter programs, and that we are also opening up the BrainTransporter thinking in a broader way, also potentially for other areas, and other companies' projects for the future as well. So I think it really strengthens the position. So it does not mean that we are, uh, lowering the ambition in any of our projects, quite the contrary, we are increasing our efforts in all our BrainTransporter linked programs and in that technology platform as well.

Anders Martin-Löf
49:21 - 49:54

Maybe we should clarify a little bit on the timelines for the research validation agreement. Gunilla mentioned that it would take roughly two years, but maybe we should clarify that we are thinking more towards the end of 2025 to get the results, not mid-2026, given that we are right now in mid-2024. So, two years from now would be 2026. Sorry. And I think you were thinking from the beginning of 2024 to the end of 2025, so roughly the same timeframe as when we expect to become ready for clinical trials.

Gunilla Osswald
49:55 - 49:56

Thank you, Anders.

Oskar Bosson
49:57 - 50:11

And thank you. Then one question from Peter refers to AI and utilizing AI in formal development. Can we say anything about our efforts in this area?

Gunilla Osswald
50:12 - 51:40

Absolutely. I think it's really important to be part of the AI explosion. And definitely, we have some pilot projects ongoing at BioArctic, and AI is typically used in different areas, like emerging areas. With regard to side effect profiles in the future and so forth. And also, there are initiatives ongoing in clinical trials, even though we are not utilizing it for our own studies right now, like where you can use AI with patients. But I think this is an area that we are clearly watching. And AI is built into many different areas already today. So, I think it's important for us and all others to be in this. I think it will be a part. But it's really important how you do it and that you do it in a safe way and so forth. And you realize the opportunities, but also mitigate some of the risks that are linked to AI. So I'll not go into any details right now, but maybe we can do that in the future and tell you about some of the examples. But we are using it and will be using it more in the future.

Oskar Bosson
51:43 - 52:13

Thank you. I don't see any more written questions online. Operator, are there any more questions? Waiting on the phone. It doesn't seem that way. So I guess that concludes our call today. And thank you, everybody, for listening in. And thank you, Neal and Anders, for being here for the presentation and Q&A. Thank you. See you next time.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…